Laboratory of Hematology-Oncology, Department of Pathology, European Institute of Oncology, 20141 Milan, Italy.
Breast. 2011 Oct;20 Suppl 3:S61-2. doi: 10.1016/S0960-9776(11)70296-X.
Anti-angiogenic drugs have gained international approval for the therapy of advanced breast, lung, colo-rectal, kidney and central nervous system cancer. However, the clinical benefit associated with the use of these drugs has been so far limited.
This review discuss the possible rational developments of a new generation anti-angiogenic drugs.
Since most of the biological and clinical activity of the currently available generation of anti-angiogenic drugs targets VEGF and its related pathways, it seems relevant to (1) better understand mechanisms of resistance and/or escape from anti-VEGF and (2) identify and validate vascular targets complementary to anti-VEGF.
抗血管生成药物已获得国际批准，用于治疗晚期乳腺癌、肺癌、结肠直肠癌、肾癌和中枢神经系统癌症。然而，迄今为止，这些药物的临床应用获益有限。
本综述讨论了新一代抗血管生成药物的合理发展方向。
由于目前可用的抗血管生成药物一代的大多数生物学和临床活性都针对 VEGF 及其相关途径，因此（1）更好地了解抗 VEGF 的耐药机制和/或逃逸机制，以及（2）确定和验证与抗 VEGF 互补的血管靶点似乎是相关的。
